Bliss GVS Pharma (BOM:506197) Payments of Debt: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506197 Bliss GVS Pharma Ltd BOM:506197
58 GF Score
Price ₹616.40
GF Value ₹170.51
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Bliss GVS Pharma Payments of Debt?

Bliss GVS Pharma BOM:506197 +5.00% 58 Payments of Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:506197 with a GF Score™ of 58/100 and a GF Value™ of ₹170.51 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Bliss GVS Pharma's Payments of Debt for the three months ended in Jun. 2026 was ₹0 Mil.

Bliss GVS Pharma's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Bliss GVS Pharma Payments of Debt Related Terms

Bliss GVS Pharma Payments of Debt Historical Data

* Premium members only.

The historical data trend for Bliss GVS Pharma's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bliss GVS Pharma Payments of Debt Chart

Bliss GVS Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -263.61 -538.95 -243.84 -717.47 -643.66

Bliss GVS Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:506197
58GF Score
Bliss GVS Pharma Ltd BOM:506197
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bliss GVS Pharma Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of ₹0 Mil mean?
Bliss GVS Pharma (BOM:506197) has a Payments of Debt of ₹0 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Bliss GVS Pharma and its competitors.
Is Bliss GVS Pharma's Payments of Debt too high?
Bliss GVS Pharma's current Payments of Debt is ₹0 Mil. Overall, Bliss GVS Pharma has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's Payments of Debt compare to ZTS?
Bliss GVS Pharma's Payments of Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Bliss GVS Pharma and its competitors. Bliss GVS Pharma's current Payments of Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (BOM:506197) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹170.51, compared to a current price of ₹616.40 — trading 261.5% above its estimated fair value. The current Payments of Debt is ₹0 Mil. Bliss GVS Pharma's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Bliss GVS Pharma (BOM:506197), the current Payments of Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?

Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued. The current stock price of ₹616.40 is trading 261.5% above its estimated GF Value™ of ₹170.51. GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.

Key valuation signals for BOM:506197:

  • Payments of Debt: ₹0 Mil
  • GF Value™: ₹170.51 vs. price of ₹616.40 (261.5% above fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bliss GVS Pharma Business Description

Other Exchanges BLISSGVS:India
Address Saki Vihar Road, 102, Hyde Park, Andheri (East), Mumbai, MH, IND, 400072
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
58GF Score

Get the complete analysis for BOM:506197

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹616.40
Price
₹170.51
GF Value